Huntington Disease

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 207-266

  Wagner, Laura A ^a   Menalled, Liliana ^b   Goumeniouk, Alexander D ^c   Brunner, Daniela ^b,d   Leavitt, Blair R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PSYCHOGENICS INC   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884894612     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00018-7     Document Type: Chapter

References (241)

1. M.R. Hayden (1981) Huntington’s Chorea. Berlin: Springer
2. G. Huntington (1872) On Chorea. The Medical and Surgical Reporter: A Weekly Journal 26(15), 317-321.
3. W. Osler (1894) On Chorea and Choreiform Affections. Philadelphia: P. Blakston, Son & Co.
4. Gusella, J.F., Wexler, N.S., Conneally, P.M., Naylor, S.L., Anderson, M.A., Tanzi, R.E., et al. (1983). A polymorphic DNA marker genetically linked to Huntingtons-disease, Nature, 306(5940) 234–238.
5. M.E. MacDonald, C.M. Ambrose, M.P. Duyao, R.H. Myers, C. Lin, L. Srinidhi, et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons-disease chromosomes. Cell Cell 72(6), 971-983.
6. P.S. Harper (1991) Huntington’s Disease. London: B Saunders Co.
7. A.B. Young, I. Shoulson, J.B. Penney, S. Starosta-Rubinstein, F. Gomez, H. Travers, et al. (1986) Huntington’s disease in Venezuela: Neurologic features and functional decline. Neurology 36(2), 244-249.
8. J.G. van Dijk, E.A. van der Velde, R.A. Roos and G.W. Bruyn (1986) Juvenile Huntington disease. Hum Genet 73(3), 235-239.
9. N. Butters, J. Wolfe, M. Martone, E. Granholm and L.S. Cermak (1985) Memory disorders associated with Huntington’s disease: Verbal recall, verbal recognition and procedural memory. Neuropsychologia 23(6), 729-743.
10. K.K. Zakzanis (1998) The subcortical dementia of Huntington's disease. J Clin Exp Neuropsychol 20(4), 565-578.
11. K.E. A Anderson and K.S. Marder (2001) An overview of psychiatric symptoms in Huntington's disease. Curr Psychiatry Rep 3(5), 379-388.
12. S. Lovestone, S. Hodgson, P. Sham, A.M. Differ and R. Levy (1996) Familial psychiatric presentation of Huntington’s disease. J Med Genet 33(2), 128-131.
13. J.M. van Raamsdonk, Z. Murphy, D.M. Selva, R. Hamidizadeh, J. Pearson, A. Petersen, et al. (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26(3), 512-520.
14. A.J. Morton, N.I. Wood, M.H. Hastings, C. Hurelbrink, R.A. Barker and E.S. Maywood (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci 25(1), 157-163.
15. P.R. Sanberg, H.C. Fibiger and R.F. Mark (1981) Body-weight and dietary factors in Huntingtons-disease patients compared with matched controls. Med J Aust 1(8), 407-409.
16. R.E. Pratley, A.D. Salbe, E. Ravussin and J.N. Caviness (2000) Higher sedentary energy expenditure in patients with Huntington’s disease. Ann Neurol 47(1), 64-70.
17. A.M. Gaba, K. Zhang, K. Marder, C.B. Moskowitz, P. Werner and C.N. Boozer (2005) Energy balance in early-stage Huntington disease. Am J Clin Nutr 81(6), 1335-1341.
18. S.E. Andrew, Y.P. Goldberg, B. Kremer, H. Telenius, J. Theilmann, S. Adam, et al. (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4(4), 398-403.
19. R.R. Brinkman, M.M. Mezei, J. Theilmann, E. Almqvist and M.R. Hayden (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60(5), 1202-1210.
20. M. Duyao, C. Ambrose, R. Myers, A. Novelletto, F. Persichetti, M. Frontali, et al. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4(4), 387-392.
21. A. Semaka, S. Creighton, S. Warby and M.R. Hayden (2006) Predictive testing for Huntington disease: Interpretation and significance of intermediate alleles. Clin Genet 70(4), 283-294.
22. D. Falush, E.W. Almqvist, R.R. Brinkmann, Y. Iwasa and M.R. Hayden (2001) Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial under ascertainment of late-onset cases. Am J Hum Genet 68(2), 373-385.
23. H. Telenius, H.P. Kremer, J. Theilmann, S.E. Andrew, E. Almqvist, M. Anvret, et al. (1993) Molecular analysis of juvenile Huntington disease: The major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 2(10), 1535-1540.
24. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird and E.P. Richardson Jr. (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44(6), 559-577.
25. J.C. A Hedreen and S.E. Folstein (1995) Early loss of neostriatal striosome neurons in Huntington’s disease. J Neuropathol Exp Neurol 54(1), 105-120.
26. A. Reiner, R.L. Albin, K.D. Anderson, C.J. D’Amato, J.B. Penney and A.B. Young (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85(15), 5733-5737.
27. R.L. Albin, A.B. Young and J.B. Penney (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12(10), 366-375.
28. J.C. Hedreen, C.E. Peyser, S.E. Folstein and C.A. Ross (1991) Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett 133(2), 257-261.
29. E. Spargo, I.P. Everall and P.L. Lantos (1993) Neuronal loss in the hippocampus in Huntington’s disease: A comparison with HIV infection. J Neurol Neurosurg Psychiatr 56(5), 487-491.
30. M.A. A Nance and R.H. Myers (2001) Juvenile onset Huntington's disease – clinical and research perspectives. Ment Retard Dev Disabil Res Rev 7(3), 153-157.
31. S.W. Davies, M. Turmaine, B.A. Cozens, M. Difiglia, A.H. Sharp, C.A. Ross, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell Cell 90(3), 537-548.
32. M. Difiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334), 1990-1993.
33. Y. Robitaille, I. Lopes-Cendes, M. Becher, G. Rouleau and A.W. Clark (1997) The neuropathology of CAG repeat diseases: Review and update of genetic and molecular features. Brain Pathol 7(3), 901-926.
34. S. Ramaswamy, K.M. Shannon and J.H. Kordower (2007) Huntington’s disease: Pathological mechanisms and therapeutic strategies. Cell Transplant 16(3), 301-312.
35. M.M. A Fan and L.A. Raymond (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington’s disease. Prog Neurobiol 81(5–6), 272-293.
36. M.M. Zeron, O. Hansson, N.S. Chen, C.L. Wellington, B.R. Leavitt, P. Brundin, et al. (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 33(6), 849-860.
37. O. Hansson, A. Petersen, M. Leist, P. Nicotera, R.F. Castilho and P. Brundin (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 96(15), 8727-8732.
38. J.G. Hodgson, N. Agopyan, C.A. Gutekunst, B.R. Leavitt, F. LePiane, R. Singaraja, et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1), 181-192.
39. E.J. Slow, J. van Raamsdonk, D. Rogers, S.H. Coleman, R.K. Graham, Y. Deng, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13), 1555-1567.
40. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, et al. (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5(8), 731-736.
41. T.S. Tang, H.P. Tu, E.Y.W. Chan, A. Maximov, Z.N. Wang, C.L. Wellington, et al. (2003) Huntingtin and Huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39(2), 227-239.
42. E. Scherzinger, R. Lurz, M. Turmaine, L. Mangiarini, B. Hollenbach, R. Hasenbank, et al. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell Cell 90(3), 549-558.
43. J.M. Edwardson, C.T. Wang, B. Gong, A. Wyttenbach, J.H. Bai, M.B. Jackson, et al. (2003) Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J Biol Chem 278(33), 30849-30853.
44. C.L. Benn, E.J. Slow, L.A. Farrell, R. Graham, Y. Deng, M.R. Hayden, et al. (2007) Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease. Neuroscience 147(2), 354-372.
45. S. Gunawardena, L.S. Her, R.G. Brusch, R.A. Laymon, I.R. Niesman, B. Gordesky-Gold, et al. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic PolyQ proteins in Drosophila. Neuron 40(1), 25-40.
46. W.C. Lee, M. Yoshihara and J.T. Littleton (2004) Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington’s disease. Proc Natl Acad Sci USA 101(9), 3224-3229.
47. J.H. Cha (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23(9), 387-392.
48. C.A. Ross (1997) Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19(6), 1147-1150.
49. E.J. Slow, R.K. Graham, A.P. Osmand, R.S. Devon, G. Lu, Y. Deng, et al. (2005) Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 102(32), 11402-11407.
50. C.A. Gutekunst, S.H. Li, H. Yi, J.S. Mulroy, S. Kuemmerle, R. Jones, et al. (1999) Nuclear and neuropil aggregates in Huntington’s disease: Relationship to neuropathology. J Neurosci 19(7), 2522-2534.
51. S. Kuemmerle, C.A. Gutekunst, A.M. Klein, X.J. Li, S.H. Li, M.F. Beal, et al. (1999) Huntingtin aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 46(6), 842-849.
52. F. Saudou, S. Finkbeiner, D. Devys and M.E. Greenberg (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell Cell 95(1), 55-66.
53. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal and S. Finkbeiner (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431(7010), 805-810.
54. B.R. Leavitt, C.L. Wellington and M.R. Hayden (1999) Recent insights into the molecular pathogenesis of Huntington disease. Semin Neurol 19(4), 385-395.
55. R.K. Graham, Y. Deng, E.J. Slow, B. Haigh, N. Bissada, G. Lu, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell Cell 125(6), 1179-1191.
56. Y.A. A Grimbergen and R.A. Roos (2003) Therapeutic options for Huntington's disease. Curr Opin Investig Drugs 4(1), 51-54.
57. R.M. A Bonelli and P. Hofmann (2004) A review of the treatment options for Huntington's disease. Expet Opin Pharmacother 5(4), 767-776.
58. N.A. De Marchi and R. Mennella (2000) Huntington’s disease and its association with psychopathology. Harv Rev Psychiatr 7(5), 278-289.
59. C. Vitale, M.T. Pellecchia, D. Grossi, N. Fragassi, T. Cuomo, L. Di Maio, et al. (2001) Unawareness of dyskinesias in Parkinson’s and Huntington’s diseases. Neurolo Sci 22(1), 105-106.
60. A.N. Barr, J.H. Fischer, W.C. Koller, A.L. Spunt and A. Singhal (1988) Serum haloperidol concentration and choreiform movements in Huntingtons-disease. Neurology 38(1), 84-88.
61. F. Squitieri, M. Cannella, A. Porcellini, L. Brusa, M. Simonelli and S. Ruggieri (2001) Short-term effects of olanzapine in Huntington disease. Neuropsychiatr Neuropsychol Behav Neurol 14(1), 69-72.
62. R.M. A Bonelli and P. Hofmann (2002) Olanzapine for Huntington’s disease: An open label study. Eur Neuropsychopharmacol 12 S367.
63. Stahl, S. (2000). Essential Psychopharmacology, 2nd edition, Cambridge University Press, Cambridge.
64. K.A. Melkersson and M.L. Dahl (2004) Adverse metabolic effects associated with atypical antipsychotics – Literature review and clinical implications. Drugs 64(7), 701-723.
65. F.J. Marshall, F. Walker, S. Frank, D. Oakes, S. Plumb, S.A. Factor, et al. (2006) Tetrabenazine as antichorea therapy in Huntington disease – A randomized controlled trial. Neurology 66(3), 366-372.
66. C. Kenney, C. Hunter, N. Mejia and J. Jankovic (2006) Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 29(5), 259-264.
67. Compendium of Pharmaceuticals and Specialties (2002). 37th edition.
68. J.B. Peiris, H. Boralessa and N.D.W. Lionel (1976) Clonazepam in treatment of choreiform activity. Med J Aust 1(8), 225-227.
69. J.T. Stewart (1988) Treatment of Huntingtons-disease with clonazepam. South Med J 81(1), 102.
70. L.V. Metman, M.J. Morris, C. Farmer, M. Gillespie, K. Mosby, J. Wuu, et al. (2002) Huntington’s disease – A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59(5), 694-699.
71. S.E. Folstein (1989) The psychopathology of Huntingtons-disease. J Nerv Ment Dis 177(10), 645.
72. A. Beister, P. Kraus, W. Kuhn, M. Dose, A. Weindl and M. Gerlach (2004) The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm-Suppl (68), 117-122.
73. M. de Tommaso, N. Specchio, V. Sciruicchio, O. Difruscolo and L.M. Specchio (2004) Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord 19(12), 1516-1518.
74. P. Petrikis, C. Andreou, A. Piachas, V.P. Bozikas and A. Karavatos (2004) Treatment of Huntington's disease with galantamine. Int Clin Psychopharmacol 19(1), 49-50.
75. H.H. Fernandez, J.H. Friedman, J. Grace and S. Beason-Hazen (2000) Donepezil for Huntington’s disease. Mov Disord 15(1), 173-176.
76. K. Marder, H. Zhao, R.H. Myers, M. Cudkowicz, E. Kayson, K. Kieburtz, et al. (2000) Rate of functional decline in Huntington’s disease. Neurology 54(2), 452-458.
77. D.P. Leonard, M.A. Kidson, J.G.E. Brown, P.J. Shannon and S. Taryan (1975) Double-blind trial of lithium-carbonate and haloperidol in Huntingtons-chorea. Aust New Zeal J Psychiatr 9(2), 115-118.
78. L.E. Goedhard, J.J. Stolker, E.R. Heerdink, H.L.I. Nijman, B. Olivier and T.C.G. Egberts (2006) Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiatr 67(7), 1013.
79. D. Paleacu, M. Anca and N. Giladi (2002) Olanzapine in Huntington’s disease. Acta Neurol Scand 105(6), 441-444.
80. M.A. Alpay and W.J. Koroshetz (2006) Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics 47(1), 70-72.
81. J.M. Meinhold, L.M. Blake, L.J. Mini, J.A. Welge, M. Schwiers and A. Hughes (2005) Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia. Drugs Aging 22(7), 615-626.
82. D.A. Wirshing, W.C. Wirshing, L. Kysar, M.A. Berisford, D. Goldstein, J. Pashdag, et al. (1999) Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatr 60(6), 358-363.
83. M. Fava (2000) Weight gain and antidepressants. J Clin Psychiatr 61 37-41.
84. S.A. Montgomery, P.E. Reimitz and M. Zivkov (1998) Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study. Int Clin Psychopharmacol 13(2), 63-73.
85. S.M. Stahl, L.S. Zhang, C. Damatarca and M. Grady (2003) Brain-circuits determine destiny in depression: A novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatr 64 6-17.
86. C.E. Peyser, M. Folstein, G.A. Chase, S. Starkstein, J. Brandt, J.R. Cockrell, et al. (1995) Trial of D-Alpha-Tocopherol in Huntingtons-Disease. Am J Psychiatr 152(12), 1771-1775.
87. B. Kremer, C.M. Clark, E.W. Almqvist, L.A. Raymond, P. Graf, C. Jacova, et al. (1999) Influence of lamotrigine on progression of early Huntington disease – A randomized clinical trial. Neurology 53(5), 1000-1011.
88. K. Kieburtz, W. Koroshetz, M. McDermott, M.F. Beal, J.T. Greenamyre, C.A. Ross, et al. (2001) A randomized, placebo-controlled trial of coenzyme Q(10) and remacemide in Huntington's disease. Neurology 57(3), 397-404.
89. F.J. Marshall, M. Cudkowicz, M. Hayden, K. Kieburtz, H.W. Zhao, J. Penney, et al. (2003) Dosage effects of riluzole in Huntington’s disease – A multicenter placebo-controlled study. Neurology 61(11), 1551-1556.
90. H. Murck, M. Manku, B.K. Puri, B.R. Leavitt, M.R. Hayden, C.A. Ross, et al. (2005) Ethyl-EPA in Huntington’s disease: A double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatr 76
91. S.M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, et al. (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′ dG. Neurology 66(2), 250-252.
92. R.M. Bonelli, A. Hoedl, H.P. Kapfhammer and G.K. Wenning (2006) Psychiatric management of Huntington’s disease: An evidence-based review. J Neurol Sci 248(1-2), 281.
93. M. Bauer, M. Alda, J. Priller and L.T. Young (2003) Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36 S250-sS254.
94. O. Aydemir, A. Deveci and F. Taneli (2005) The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study. Progr Neuro Psychopharmacol Biol Psychiatr 29(2), 261-265.
95. L. Brusa, V. Versace, G. Koch, G. Bernardi, C. Iani, P. Stanzione, et al. (2005) Improvement of choreic movements by 1Hz repetitive transcranial magnetic stimulation in Huntington’s disease patients. Ann Neurol 58(4), 655-656.
96. M. de Tommaso, V. Sciruicchio, N. Specchio, O. Di Fruscolo, C. Cormio, M. Barulli, et al. (2005) Efficacy of levetiracetam in Huntington’s disease. J Neurol Sci 238 S503-S504.
97. M.F. Beal, E. Brouillet, B.G. Jenkins, R.J. Ferrante, N.W. Kowall, J.M. Miller, et al. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13(10), 4181-4192.
98. E. Brouillet, P. Hantraye, R.J. Ferrante, R. Dolan, A. Leroywillig, N.W. Kowall, et al. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92(15), 7105-7109.
99. E. Brouillet, F. Conde, M.F. Beal and P. Hantraye (1999) Replicating Huntington’s disease phenotype in experimental animals. Prog Neurobiol 59(5), 427-468.
100. A.C. Ludolph, F. He, P.S. Spencer, J. Hammerstad and M. Sabri (1991) 3-Nitropropionic acid – exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18(4), 492-498.
101. M.F. Beal, R.J. Ferrante, K.J. Swartz and N.W. Kowall (1991) Chronic quinolinic acid lesions in rats closely resemble Huntingtons-disease. J Neurosci 11(6), 1649-1659.
102. G.T. Barnes, M.P. Duyao, C.M. Ambrose, S. Mcneil, F. Persichetti, J. Srinidhi, et al. (1994) Mouse Huntingtons-disease gene homolog (Hdh). Somat Cell Mol Genet 20(2), 87-97.
103. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell Cell 87(3), 493-506.
104. G.A. Laforet, E. Sapp, K. Chase, C. McIntyre, F.M. Boyce, M. Campbell, et al. (2001) Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. J Neurosci 21(23), 9112-9123.
105. G. Schilling, M.W. Becher, A.H. Sharp, H.A. Jinnah, K. Duan, J.A. Kotzuk, et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8(3), 397-407.
106. A. Yamamoto, J.J. Lucas and R. Hen (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell Cell 101(1), 57-66.
107. O.A. Andreassen, R.J. Ferrante, A. Dedeoglu and M.F. Beal (2001) Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport 12(15), 3371-3373.
108. O.A. Andreassen, A. Dedeoglu, R.J. Ferrante, B.G. Jenkins, K.L. Ferrante, M. Thomas, et al. (2001) Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis 8(3), 479-491.
109. R.J. Ferrante, O.A. Andreassen, B.G. Jenkins, A. Dedeoglu, S. Kuemmerle, J.K. Kubilus, et al. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci 20(12), 4389-4397.
110. R.J. Ferrante, O.A. Andreassen, A. Dedeoglu, K.L. Ferrante, B.G. Jenkins, S.M. Hersch, et al. (2002) Therapeutic effects of coenzyme Q(10) and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22(5), 1592-1599.
111. S. Mievis, C. Ledent and D. Blum (2005) Lack of minocycline efficiency in genetic models of Huntington’s disease. J Neurol Neurosurg Psychiatr 76
112. M. Diaz-Hernandez, J. Torres-Peraza, A. Salvatori-Abarca, M.A. Moran, P. Gomez-Ramos, J. Alberch, et al. (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington’s disease. J Neurosci 25(42), 9773-9781.
113. R.J. Carter, L.A. Lione, T. Humby, L. Mangiarini, A. Mahal, G.P. Bates, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19(8), 3248-3257.
114. E.C. Stack, J.K. Kubilus, K. Smith, K. Cormier, S.J. Del Signore, E. Guelin, et al. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington’s disease transgenic mice. J Comp Neurol 490(4), 354-370.
115. Z.X. Yu, S.H. Li, J. Evans, A. Pillarisetti, H. Li and X.J. Li (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington’s disease. J Neurosci 23(6), 2193-2202.
116. L.A. Lione, R.J. Carter, M.J. Hunt, G.P. Bates, A.J. Morton and S.B. Dunnett (1999) Selective discrimination learning impairments in mice expressing the human Huntington’s disease mutation. J Neurosci 19(23), 10428-10437.
117. C. Cepeda, R.S. Hurst, C.R. Calvert, E. Hernandez-Echeagaray, O.K. Nguyen, E. Jocoy, et al. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23(3), 961-969.
118. M.B. Bogdanov, O.A. Andreassen, A. Dedeoglu, R.J. Ferrante and M.F. Beal (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington’s disease. J Neurochem 79(6), 1246-1249.
119. E. Hockly, B. Woodman, A. Mahal, C.M. Lewis and G. Bates (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 61(5), 469-479.
120. S.M. A Hersch and R.J. Ferrante (2004) Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics 1 298-306.
121. J.M. van Raamsdonk, J. Pearson, E.J. Slow, S.M. Hossain, B.R. Leavitt and M.R. Hayden (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington’s disease. J Neurosci 25(16), 4169-4180.
122. J.M. Ordway, S. TallaksenGreene, C.A. Gutekunst, E.M. Bernstein, J.A. Cearley, H.W. Wiener, et al. (1997) Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell Cell 91(6), 753-763.
123. P.H. Reddy, M. Williams, V. Charles, L. Garrett, L. Pike-Buchanan, W.O. Whetsell, et al. (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20(2), 198-202.
124. R.K. Graham, E.J. Slow, Y. Deng, N. Bissada, G. Lu, J. Pearson, et al. (2006) Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis 21(2), 444-455.
125. J.M. van Raamsdonk, Z. Murphy, E.J. Slow, B.R. Leavitt and M.R. Hayden (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14(24), 3823-3835.
126. Y. Tanaka, S. Igarashi, M. Nakamura, J. Gafni, C. Torcassi, G. Schilling, et al. (2006) Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 21(2), 381-391.
127. J.K. White, W. Auerbach, M.P. Duyao, J.P. Vonsattel, J.F. Gusella, A.L. Joyner, et al. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington’s disease CAG expansion. Nat Genet 17(4), 404-410.
128. M.S. Levine, G.J. Klapstein, A. Koppel, E. Gruen, C. Cepeda, M.E. Vargas, et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res 58(4), 515-532.
129. P.F. Shelbourne, N. Killeen, R.F. Hevner, H.M. Johnston, L. Tecott, M. Lewandoski, et al. (1999) A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8(5), 763-774.
130. V.C. Wheeler, J.K. White, C.A. Gutekunst, V. Vrbanac, M. Weaver, X.J. Li, et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in Hdh(Q92) and Hdh(Q111) knock-in mice. Hum Mol Genet 9(4), 503-513.
131. C.H. Lin, S. Tallaksen-Greene, W.M. Chien, J.A. Cearley, W.S. Jackson, A.B. Crouse, et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 10(2), 137-144.
132. L.B. Menalled, J.D. Sison, I. Dragatsis, S. Zeitlin and M.F. Chesselet (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465(1), 11-26.
133. L.B. A Menalled and M.F. Chesselet (2002) Mouse models of Huntington’s disease. Trends Pharmacol Sci 23(1), 32-39.
134. S. Zeitlin, J.P. Liu, D.L. Chapman, V.E. Papaioannou and A. Efstratiadis (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntingtons-disease gene homolog. Nat Genet 11(2), 155-163.
135. I. Dragatsis, A. Efstratiadis and S. Zeitlin (1998) Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 125(8), 1529-1539.
136. A. Reiner, N. Del Mar, C.A. Meade, H.T. Yang, I. Dragatsis, S. Zeitlin, et al. (2001) Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice. J Neurosci 21(19), 7608-7619.
137. I. Dragatsis, M.S. Levine and S. Zeitlin (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26(3), 300-306.
138. J.M. van Raamsdonk, J. Pearson, D.A. Rogers, N. Bissada, A.W. Vogl, M.R. Hayden, et al. (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14(10), 1379-1392.
139. B. Woodman, R. Butler, C. Landles, M.K. Lupton, J. Tse, E. Hockly, et al. (2007) The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 72(2–3), 83-97.
140. S. Irwin (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13(3), 222-257.
141. R.J. Hamm, B.R. Pike, D.M. O’Dell, B.G. Lyeth and L.W. Jenkins (1994) The rotarod test: An evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11(2), 187-196.
142. M.A. Hickey, K. Gallant, G.G. Gross, M.S. Levine and M.F. Chesselet (2005) Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20(1), 1-11.
143. J.M. van Raamsdonk, M. Metzler, E. Slow, J. Pearson, C. Schwab, J. Carroll, et al. (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26(1), 189-200.
144. V.J. Bolivar, K. Manley and A. Messer (2004) Early exploratory behavior abnormalities in R6/1 Huntington’s disease transgenic mice. Brain Res 1005(1–2), 29-35.
145. T. Foroud, E. Siemers, D. Kleindorfer, D.J. Bill, M.E. Hodes, J.A. Norton, et al. (1995) Cognitive scores in carriers of Huntington’s disease gene compared to noncarriers. Ann Neurol 37(5), 657-664.
146. V. Hahn-Barma, B. Deweer, A. Durr, C. Dode, J. Feingold, B. Pillon, et al. (1998) Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J Neurol Neurosurg Psychiatr 64(2), 172-177.
147. E. Gomez-Tortosa, A. del Barrio, P.J. Garcia Ruiz, R.S. Pernaute, J. Benitez, A. Barroso, et al. (1998) Severity of cognitive impairment in juvenile and late-onset Huntington disease. Arch Neurol 55(6), 835-843.
148. G.E. Berrios, A.C. Wagle, I.S. Markova, S.A. Wagle, L.W. Ho, D.C. Rubinsztein, et al. (2001) Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington’s disease gene carriers. Psychiatr Res 102(3), 217-225.
149. D.A. Craufurd and J. Snowden (2002) Neuropsychological and neuropsychiatric aspects of Huntington’s disease. G. Bates, P.S. Harper, L. Jones (Eds) Huntington’s Disease 3rd ed Oxford: Oxford University Press 62-94.
150. K.W. Lange, B.J. Sahakian, N.P. Quinn, C.D. Marsden and T.W. Robbins (1995) Comparison of executive and visuospatial memory function in Huntington’s disease and dementia of Alzheimer type matched for degree of dementia. J Neurol Neurosurg Psychiatr 58(5), 598-606.
151. N.R. Swerdlow, J. Paulsen, D.L. Braff, N. Butters, M.A. Geyer and M.R. Swenson (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatr 58(2), 192-200.
152. K.W. Lange, F. Javoy-Agid, Y. Agid, P. Jenner and C.D. Marsden (1992) Brain muscarinic cholinergic receptors in Huntington’s disease. J Neurol 239(2), 103-104.
153. M. Koch (1996) The septohippocampal system is involved in prepulse inhibition of the acoustic startle response in rats. Behav Neurosci 110(3), 468-477.
154. J.M. Birrell J.M. a and V.J. Brown (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20(11), 4320-4324.
155. E.M. Tunbridge, D.M. Bannerman, T. Sharp and P.J. Harrison (2004) Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 24(23), 5331-5335.
156. G. Colacicco, H. Welzl, H.P. Lipp and H. Wurbel (2002) Attentional set-shifting in mice: Modification of a rat paradigm, and evidence for strain-dependent variation. Behav Brain Res 132(1), 95-102.
157. S.P. Brooks, H. Betteridgea, R.C. Truernan, L. Jones and S.B. Dunnett (2006) Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington’s disease. Brain Res Bull 69(4), 452-457.
158. R. Morris (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1), 47-60.
159. F. Block, M. Kunkel and M. Schwarz (1993) Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats. Neurosci Lett 149(2), 126-128.
160. J.A. Saint-Cyr, A.E. Taylor and A.E. Lang (1988) Procedural learning and neostriatal dysfunction in man. Brain 111(Pt 4), 941-959.
161. J. Micheau, G. Riedel, E.L. Roloff, J. Inglis and R.G. Morris (2004) Reversible hippocampal inactivation partially dissociates how and where to search in the water maze. Behav Neurosci 118(5), 1022-1032.
162. K.P. Murphy, R.J. Carter, L.A. Lione, L. Mangiarini, A. Mahal, G.P. Bates, et al. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20(13), 5115-5123.
163. D. Brunner, M.C. Buhot, R. Hen and M. Hofer (1999) Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice. Behav Neurosci 113(3), 587-601.
164. R. Gerlai (1996) Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype? Trends Neurosci 19(5), 177-181.
165. A. Weller, A.C. Leguisamo, L. Towns, S. Ramboz, E. Bagiella, M. Hofer, et al. (2003) Maternal effects in infant and adult phenotypes of 5HT1A and 5HT1B receptor knockout mice. Dev Psychobiol 42(2), 194-205.
166. E. Hockly, P.M. Cordery, B. Woodman, A. Mahal, A. van Dellen, C. Blakemore, et al. (2002) Environmental enrichment slows disease progression in R61/2 Huntington’s disease mice. Ann Neurol 51(2), 235-242.
167. T.L. Spires, H.E. Grote, N.K. Varshney, P.M. Cordery, A. van Dellen, C. Blakemore, et al. (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington’s disease, indicating a possible disease mechanism. J Neurosci 24(9), 2270-2276.
168. Patterson-Kane, E.G., Farnworth, M.J. (2006). Noise exposure, music, and animals in the laboratory: A commentary based on laboratory Animal Refinement and Enrichment Forum (LAREF) discussions. J Appl Animal Welfare Sci 9(4):327–332.
169. R.J. Carter, M.J. Hunt and A.J. Morton (2000) Environmental stimulation increases survival in mice transgenic for exon I of the Huntington’s disease gene. Mov Disord 15(5), 925-937.
170. K.A. Claxton and J. Posnett (1996) An economic approach to clinical trial design and research priority-setting. Health Econ 5(6), 513-524.
171. T.T. Chen (1997) Optimal three-stage designs for phase II cancer clinical trials. Stat Med 16(23), 2701-2711.
172. K. Kieburtz, W. Koroshetz, M. McDermott, M.F. Beal, J.T. Greenamyre, C.A. Ross, et al. (2001) A randomized, placebo-controlled trial of coenzyme Q(10) and remacemide in Huntington's disease. Neurology 57(3), 397-404.
173. M. Farrington, T.G. Wreghitt, A.M.L. Lever, S.B. Dunnett, A.E. Rosser and R.A. Barker (2006) Neural transplantation in Huntington’s disease: The NEST-UK donor tissue microbiological screening program and review of the literature. Cell Transplant 15(4), 279-294.
174. V. Gaura, A.C. Bachoud-Levi, M.J. Ribeiro, J.P. Nguyen, V. Frouin, S. Baudic, et al. (2004) Striatal neural grafting improves cortical metabolism in Huntington’s disease patients. Brain 127 65-72.
175. E. Ferrada, V. Arancibia, B. Loeb, E. Norambuena, C. Olea-Azar and J.P. Huidobro-Toro (2007) Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer’s and Huntington’s disease therapy. Neurotoxicology 28(3), 445-449.
176. A. Lavandeira (2002) Orphan drugs: Legal aspects, current situation Haemophilia. Haemophilia 8(3), 194-198.
177. G.P. A Bates and E. Hockly (2003) Experimental therapeutics in Huntington’s disease: Are models useful for therapeutic trials? Curr Opin Neurol 16(4), 465-470.
178. S.M.D. Henley, G.P. Bates and S.J. Tabrizi (2005) Biomarkers for neurodegenerative diseases. Curr Opin Neurol 18(6), 698-705.
179. H. Li, S.H. Li, H. Johnston, P.F. Shelbourne and X.J. Li (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25(4), 385-389.
180. K.M. Smith, S. Matson, W.R. Matson, K. Cormier, S.J. Del Signore, S.W. Hagerty, et al. (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington’s disease mice. Biochim Biophys Acta 1762(6), 616-626.
181. E.C. Stack, K.M. Smith, H. Ryu, K. Cormier, M. Chen, S.W. Hagerty, et al. (2006) Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington’s disease mice. Biochim Biophys Acta 1762(3), 373-380.
182. G. Schilling, A.V. Savonenko, M.L. Coonfield, J.L. Morton, E. Vorovich, A. Gale, et al. (2004) Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 187(1), 137-149.
183. A.J. Morton, M.J. Hunt, A.K. Hodges, P.D. Lewis, A.J. Redfern, S.B. Dunnett, et al. (2005) A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur J Neurosci 21(4), 855-870.
184. A. Dedeoglu, J.K. Kubilus, L. Yang, K.L. Ferrante, S.M. Hersch, M.F. Beal, et al. (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J Neurochem 85(6), 1359-1367.
185. P. Klivenyi, R.J. Ferrante, G. Gardian, S. Browne, P.E. Chabrier and M.F. Beal (2003) Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington’s disease. J Neurochem 86(1), 267-272.
186. G.V. Rebec, S.J. Barton, A.M. Marseilles and K. Collins (2003) Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14(9), 1263-1265.
187. D.L. Smith, B. Woodman, A. Mahal, K. Sathasivam, S. Ghazi-Noori, P.A. Lowden, et al. (2003) Minocycline and doxycycline are not beneficial in a model of Huntington’s disease. Ann Neurol 54(2), 186-196.
188. M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, S. Zhu, et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6(7), 797-801.
189. C.D. A Bailey and G.V. Johnson (2006) The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 27(6), 871-879.
190. van Raamsdonk, J.M., Pearson, J., Bailey, C.D., Rogers, D.A., Johnson, G.V., Hayden, M.R., et al. (2005). Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem, 95(1):210–220.
191. M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedotti, et al. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8(2), 143-149.
192. A. Dedeoglu, J.K. Kubilus, T.M. Jeitner, S.A. Matson, M. Bogdanov, N.W. Kowall, et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22(20), 8942-8950.
193. T.Y. Pang, N.C. Stam, J. Nithianantharajah, M.L. Howard and A.J. Hannan (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington’s disease transgenic mice. Neuroscience 141(2), 569-584.
194. S.E. Lazic, H.E. Grote, C. Blakemore, A.J. Hannan, A. van Dellen, W. Phillips, et al. (2006) Neurogenesis in the R6/1 transgenic mouse model of Huntington’s disease: effects of environmental enrichment. Eur J Neurosci 23(7), 1829-1838.
195. M. Glass, A. van Dellen, C. Blakemore, A.J. Hannan and R.L. Faull (2004) Delayed onset of Huntington’s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123(1), 207-212.
196. A. van Dellen, C. Blakemore, R. Deacon, D. York and A.J. Hannan (2000) Delaying the onset of Huntington’s in mice. Nature 404(6779), 721-722.
197. J.J. Clifford, J. Drago, A.L. Natoli, J.Y. Wong, A. Kinsella, J.L. Waddington, et al. (2002) Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington’s disease. Neuroscience 109(1), 81-88.
198. W. Duan, Z. Guo, H. Jiang, M. Ware, X.J. Li and M.P. Mattson (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 100(5), 2911-2916.
199. N.I. Wood, P.N. Pallier, J. Wanderer and A.J. Morton (2007) Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Neurobiol Dis 25(2), 342-353.
200. I. Sanchez, C. Mahlke and J. Yuan (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421(6921), 373-379.
201. M. Tanaka, Y. Machida, S. Niu, T. Ikeda, N.R. Jana, H. Doi, et al. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10(2), 148-154.
202. G. Gardian, S.E. Browne, D.K. Choi, P. Klivenyi, J. Gregorio, J.K. Kubilus, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem 280(1), 556-563.
203. R.J. Ferrante, H. Ryu, J.K. Kubilus, S. D’Mello, K.L. Sugars, J. Lee, et al. (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington’s disease. J Neurosci 24(46), 10335-10342.
204. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci 23(28), 9418-9427.
205. E. Hockly, V.M. Richon, B. Woodman, D.L. Smith, X. Zhou, E. Rosa, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA 100(4), 2041-2046.
206. N.I. A Wood and A.J. Morton (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington’s disease mutation. Brain Res Bull 61(4), 375-383.
207. E. Hockly, J. Tse, A.L. Barker, D.L. Moolman, J.L. Beunard, A.P. Revington, et al. (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington’s disease. Neurobiol Dis 21(1), 228-236.
208. J. Schiefer, G.B. Landwehrmeyer, H.G. Luesse, A. Sprunken, C. Puls, A. Milkereit, et al. (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington’s disease. Mov Disord 17(4), 748-757.
209. J. Schiefer, A. Sprunken, C. Puls, H.G. Luesse, A. Milkereit, E. Milkereit, et al. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 1019(1–2), 246-254.
210. S.B. Dunnett, R.J. Carter, C. Watts, E.M. Torres, A. Mahal, L. Mangiarini, et al. (1998) Striatal transplantation in a transgenic mouse model of Huntington’s disease. Exp Neurol 154(1), 31-40.
211. A. van Dellen, R. Deacon, D. York, C. Blakemore and A.J. Hannan (2001) Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. Brain Res Bull 56(3–4), 313-318.
212. N.A. Ende and R. Chen (2001) Human umbilical cord blood cells ameliorate Huntington’s disease in transgenic mice. J Med 32(3-4), 231-240.
213. T.C. Ma, J.L. Buescher, B. Oatis, J.A. Funk, A.J. Nash, R.L. Carrier, et al. (2007) Metformin therapy in a transgenic mouse model of Huntington’s disease. Neurosci Lett 411(2), 98-103.
214. M.J. A Hunt and A.J. Morton (2005) Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 166(2), 220-229.
215. J.L. McBride, S. Ramaswamy, M. Gasmi, R.T. Bartus, C.D. Herzog, E.P. Brandon, et al. (2006) Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA 103(24), 9345-9350.
216. N. Popovic, M. Maingay, D. Kirik and P. Brundin (2005) Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 193(1), 65-74.
217. D. Zala, J.C. Bensadoun, L. Pereira de Almeida, B.R. Leavitt, C.A. Gutekunst, P. Aebischer, et al. (2004) Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington’s disease transgenic mice. Exp Neurol 185(1), 26-35.
218. H.E. Grote, N.D. Bull, M.L. Howard, A. van Dellen, C. Blakemore, P.F. Bartlett, et al. (2005) Cognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine. Eur J Neurosci 22(8), 2081-2088.
219. W. Duan, Z. Guo, H. Jiang, B. Ladenheim, X. Xu, J.L. Cadet, et al. (2004) Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 55(4), 590-594.
220. P.N. Pallier, E.S. Maywood, Z.G. Zheng, J.E. Chesham, A.N. Inyushkin, R. Dyball, et al. (2007) Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of huntington’s disease. J Neurosci 27(29), 7869-7878.
221. J.M. van Raamsdonk, J. Pearson, D.A. Rogers, G. Lu, V.E. Barakauskas, A.M. Barr, et al. (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 196(2), 266-272.
222. B. Huang, J. Schiefer, C. Sass, G.B. Landwehrmeyer, C.M. Kosinski and S. Kochanek (2007) High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther 18(4), 303-311.
223. Y. Machida, T. Okada, M. Kurosawa, F. Oyama, K. Ozawa and N. Nukina (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 343(1), 190-197.
224. Y.L. Wang, W. Liu, E. Wada, M. Murata, K. Wada and I. Kanazawa (2005) Clinico-pathological rescue of a model mouse of Huntington’s disease by siRNA. Neurosci Res 53(3), 241-249.
225. S.Q. Harper, P.D. Staber, X. He, S.L. Eliason, I.H. Martins, Q. Mao, et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 102(16), 5820-5825.
226. T.W. Miller, T.L. Shirley, W.J. Wolfgang, X.W. Kang and A. Messer (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 7(5), 572-579.
227. T. Nguyen, A. Hamby and S.M. Massa (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 102(33), 11840-11845.
228. F. Norflus, A. Nanje, C.A. Gutekunst, G. Shi, J. Cohen, M. Bejarano, et al. (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis 17(2), 319-325.
229. C.D. Keene, C.M. Rodrigues, T. Eich, M.S. Chhabra, C.J. Steer and W.C. Low (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 99(16), 10671-10676.
230. B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, L.G. Oroz, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6), 585-595.
231. J.M. Gil, M. Leist, N. Popovic, P. Brundin and A. Petersen (2004) Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci 5 17.
232. M.R. Dominici, M.L. Scattoni, A. Martire, G. Lastoria, R.L. Potenza, A. Borioni, et al. (2007) Behavioral and electrophysiological effects of the adenosine A(2A) receptor antagonist SCH 58261 in R6/2 Huntington’s disease mice. Neurobiol Dis 28(2), 197-205.
233. S.Y. Chou, Y.C. Lee, H.M. Chen, M.C. Chiang, H.L. Lai, H.H. Chang, et al. (2005) CGS21680 attenuates symptoms of Huntington’s disease in a transgenic mouse model. J Neurochem 93(2), 310-320.
234. G. Schilling, M.L. Coonfield, C.A. Ross and D.R. Borchelt (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse model. Neurosci Lett 315(3), 149-153.
235. V.M. Miller, R.F. Nelson, C.M. Gouvion, A. Williams, E. Rodriguez-Lebron, S.Q. Harper, et al. (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 25(40), 9152-9161.
236. A. Zourlidou, T. Gidalevitz, M. Kristiansen, C. Landles, B. Woodman, D.J. Wells, et al. (2007) Hsp27 overexpression in the R6/2 mouse model of Huntington’s disease: chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet 16(9), 1078-1090.
237. Z. Qiu, F. Norflus, B. Singh, M.K. Swindell, R. Buzescu, M. Bejarano, et al. (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 281(24), 16672-16680.
238. C. Vacher, L. Garcia-Oroz and D.C. Rubinsztein (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington’s disease. Hum Mol Genet 14(22), 3425-3433.
239. O. Hansson, J. Nylandsted, R.F. Castilho, M. Leist, M. Jaattela and P. Brundin (2003) Overexpression of heat shock protein 70 in R6/2 Huntington’s disease mice has only modest effects on disease progression. Brain Res 970(1–2), 47-57.
240. Y. Zhang, V.O. Ona, M. Li, M. Drozda, M. Dubois-Dauphin, S. Przedborski, et al. (2003) Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington’s disease. J Neurochem 87(5), 1184-1192.
241. V.O. Ona, M. Li, J.P. Vonsattel, L.J. Andrews, S.Q. Khan, W.M. Chung, et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 399(6733), 263-267.